key: cord-0777237-z7fgmpc5
authors: Qiao, Baofu; de la Cruz, Monica Olvera
title: The Distal Polybasic Cleavage Sites of SARS-CoV-2 Spike Protein Enhance Spike Protein-ACE2 Binding
date: 2020-06-10
journal: bioRxiv
DOI: 10.1101/2020.06.09.142877
sha: 79dda14ed55bbe4c4dc52b4bf153e28dc91596ef
doc_id: 777237
cord_uid: z7fgmpc5

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein plays a crucial role in binding the human cell receptor ACE2 that is required for viral entry. Many studies have been conducted to target the structures of RBD-ACE2 binding and to design RBD-targeting vaccines and drugs. Nevertheless, mutations distal from the SARS-CoV-2 RBD also impact its transmissibility and antibody can target non-RBD regions, suggesting the incomplete role of the RBD region in the spike protein-ACE2 binding. Here, in order to elucidate distant binding mechanisms, we analyze complexes of ACE2 with the wild type spike protein and with key mutants via large-scale all-atom explicit solvent molecular dynamics simulations. We find that though distributed approximately 10 nm away from the RBD, the SARS-CoV-2 polybasic cleavage sites enhance, via electrostatic interactions and hydration, the RBD-ACE2 binding affinity. A negatively charged tetrapeptide (GluGluLeuGlu) is then designed to neutralize the positively charged arginine on the polybasic cleavage sites. We find that the tetrapeptide GluGluLeuGlu binds to one of the three polybasic cleavage sites of the SARS-CoV-2 spike protein lessening by 34% the RBD-ACE2 binding strength. This significant binding energy reduction demonstrates the feasibility to neutralize RBD-ACE2 binding by targeting this specific polybasic cleavage site. Our work enhances understanding of the binding mechanism of SARS-CoV-2 to ACE2, which may aid the design of therapeutics for COVID-19 infection. TOC: The SARS-CoV-2 spike protein-ACE2 complex showing the polybasic cleavage sites

The outbreak of the SARS-CoV-2 related disease COVID-19 has caused more than 6 million infections and over 0.3 million deaths globally. The SARS-CoV-2 spike protein exhibits two notable features; its receptor-binding domain (RBD) is optimized to bind the human cell receptor angiotensin-converting enzyme 2 (ACE2) and each subunit of the spike protein trimer has a polybasic cleavage site. 1 Given the structural similarity between the spike proteins of the SARS-CoV-2 and its close relative SARS-CoV (2003) , the RBD of the SARS-CoV-2 has been quickly recognized in targeting the ACE2 receptor, [2] [3] [4] which is required for subsequent viral entry. The atomic structures of the contact region between the SARS-CoV-2 RBD and ACE2 have been experimentally obtained by different groups. [5] [6] [7] Owing to the crucial role of the SARS-CoV-2 RBD, numerous vaccine and drug candidates have been proposed to target the RBD to inhibit the RBD-ACE2 binding. [8] [9] [10] However, more research is beginning to show that mutations distal from the RBD (non-RBD mutations) of SARS-CoV-2 also influence its transmissibility. For instance, Walls et al. 2 found that by mutating the T678NSPRRAR685 residues, which are distributed around 10 nm from the SARS-CoV-2 RBD, to a variant with T678--IL--R685, the transduction efficiency decreased in human ACE2-expressing Baby Hamster Kidney cells. The mutant D614G (a single change in the genetic code; D = aspartic acid, G = glycine) of the SARS-CoV-2 spike protein, which began spreading in Europe in February, displayed stronger transmissibility. 11 The D614 and G614 residues are located about 7 -10 nm from the SARS-CoV-2 RBD.

Surprisingly, Yuan et al. 12 found that the antibody CR3022 isolated from a recovered SARS-CoV patient targeted a highly conserved epitope of SARS-CoV-2 and SARS-CoV, which is also distal from their RBDs. That is, the antibody CR3022 does not directly bind the spike protein RBD. All these works support the significance of non-RBD mutations and non-RBD-targeting in vaccine and drug design, which remains elusive thus far.

In the present work, large scale all-atom explicit solvent molecular dynamics (MD) simulations reveal that the spike protein polybasic cleavage sites, which are distributed approximately 10 nm away from the RBD, can enhance the binding affinity between the SARS-CoV-2 RBD and ACE2. This information is used to design a negatively charged tetrapeptide, GluGluLeuGlu, that targets the polybasic cleavage sites.

The negatively charged glutamic acids (Glu) are introduced to charge neutralize the polybasic cleavage sites and the nonpolar leucine (Leu) is included to increase the hydrophobicity of the tetrapeptide, which favors binding to the polybasic cleavage site. The tetrapeptide GluGluLeuGlu is found to bind to one specific polybasic cleavage site, resulting in a remarkable weakening (34%) of the spike protein-ACE2 binding energy. Our work provides guidelines to design therapeutic peptides to inhibit SARS-CoV-2 RBD-ACE2 binding. 

Each subunit of the SARS-CoV-2 trimeric spike protein has one polybasic cleavage site (R 682RAR685). 1

The polybasic cleavage sites (R 682RAR685) have not been reported for SARS-CoV or any other lineage B coronaviruses, and therefore, they are thought to be unique to SARS-CoV-2. 2, 13, 14 In comparison to the extensive studies carried out on the SARS-CoV-2 RBD, the polybasic cleavage sites have thus far not been widely investigated, and their function remains elusive. They are believed to be related to the viral transmissibility of SARS-CoV-2. 2, 14 Moreover, they have been found to be essential for spike protein-driven viral entry into lung cells 15 .

To elucidate the influence of the polybasic cleavage sites, the wild type (WT) spike protein-ACE2 complex was investigated along with two mutants (Figure 1) . The SARS-CoV-2 spike protein-ACE2 complex was downloaded from the Zhang-Server, 16 which contains the full length of the wild type SARS-CoV-2 spike protein bound to the ACE2 receptor. The spike protein-ACE2 complex was solvated in a water box with a length of 16×18×24 nm 3 , where 0.15 M NaCl was included. All-atom MD simulation was conducted to equilibrate the system using the CHARMM 36m force field. 17 To preserve the spike protein-ACE2 binding structure the non-hydrogen atoms of the spike protein trimer and ACE2 were restrained, which were removed in the following simulations.

The WT spike protein was subsequently mutated. For mutant 1, the N679SPRRA684 residues were removed for all the three subunits of the spike protein trimer. This mutant is similar to the variant experimentally investigated (T678--IL--R685) 2 . In the case of mutant 2, the R682R683 residues were changed to E 682E683 for all three subunits of the trimeric spike protein, where E stands for negatively charged glutamic acid. For each of the three systems (WT and mutants 1 and 2) all-atom explicit solvent simulations were performed for a duration of 100 ns. And five parallel runs were carried out based on the simulation configurations at 20, 40, 60, 80, and 100 ns. See the Methods section. The five parallel simulations were employed to calculate the binding energy (Table S2 in the Supporting Information) and intermolecular hydrogen bonds between the SARS-CoV-2 RBD and ACE2. Figure 2A is the final simulation snapshot of the wild type spike protein-ACE2 complex.

The polybasic cleavage sites are located 10 -13 nm away from the RBD. In all three systems, the SARS-CoV-2 RBD stayed bound to ACE2 (Figure 2B-D) . Nevertheless, the potential energy between the RBD and ACE2, which was the summation of the intermolecular short-range Coulomb and Lennard-Jones interactions, exhibited remarkable differences ( Figure 2E) . The RBD-ACE2 binding energy for the WT spike protein is -740 ± 70 kJ/mol. The removal of N679SPRRA684 compromises the RBD-ACE2 interaction by 36% to -470 ± 50 kJ/mol, supporting that mutant 1 heavily depresses the binding affinity between the RBD and ACE2. This is in line with the experimental finding that the mutation of T 678NSPRRAR685 to a variant with T678--IL--R685 of a murine leukemia virus decreased the transduction efficiency of human ACE2-expressing Baby Hamster Kidney cells. 2 Meanwhile, the mutation from R682R683 to E682E683 decreased the RBD-ACE2 binding energy by 20% to -590 ± 40 kJ/mol. Therefore, both mutants greatly destabilized the RBD-ACE2 binding in comparison to the WT spike protein.

Note that ACE2 is highly negatively charged (-28 e), which leads to a highly negatively charged extracellular membrane surface. The Coulomb interactions favor the adsorption of positively charged species, for instance, arginine residues. Also of note is that due to the positively charged nature, arginine has been found to enhance the cellular uptake of peptides 18 and promote the therapeutic delivery of peptides across the blood-brain barrier for Alzheimer's disease 19 . Therefore, the observed drops in the RBD-ACE2 binding energy for mutants 1 and 2 could be primarily ascribed to a change in (long-range) Coulomb interactions between ACE2 and the spike protein (Table S2) , even though the polybasic cleavage sites are around 10 nm away from the RBD and ACE2. Moreover, the substitution of positively charged arginine with negatively charged glutamic acid increases protein hydration (Table S2) , which is consistent with the fact that negatively charged amino acids exhibit stronger hydration than positively charged ones. [20] [21] [22] Further analysis of the intermolecular hydrogen bonds between the RBD and ACE2 demonstrated a similar influence of the mutants (Figure 2F ). For the WT spike protein, there exist 8 ± 1 hydrogen bonds between the RBD and ACE2. This is in good agreement with the experimental finding 5 that eight RBD-ACE2 intermolecular polar interactions were suggested based on the cryo-EM structure. For mutant 1 the number of RBD-ACE2 intermolecular hydrogen bonds decreased by 60% to 3.2 ± 0.5, and by 21% (to 6.3 ± 0.8) for mutant 2. These results further support that both mutants weaken the RBD-ACE2 binding affinity, in line with the calculated RBD-ACE2 intermolecular interaction energy.

Visualization of the distribution of the RBD-ACE2 intermolecular hydrogen bonds (Figure 2B-D) suggested that balanced hydrogen bonds at both ends of the RBD-ACE2 contact region play a crucial role in stabilizing the RBD-ACE2 binding. Specifically, the number of the intermolecular hydrogen bonds decreases at both termini from the WT spike protein to the mutant 2 and to the mutant 1.

Interestingly, when we were preparing this work, an antibody CR3022 12 was reported to bind a non-RBD region of the spike protein. Here, we explore the possibility to inhibit SARS-CoV-2 RBD-ACE2 binding by neutralizing the polybasic cleavage sites. To this end, we designed an oligopeptide: a tetrapeptide GluGluLeuGlu (EELE). Negatively charged glutamic acids (Glu) were included to neutralize the positively charged arginine residues at the polybasic cleavage sites. The hydrophobic leucine (Leu) residue was introduced to decrease the hydration, as a test simulation on a tetrapeptide EEEE showed that EEEE became quickly dissolved (within 10 ns) owing to the high hydration of the negatively charged amino acids. [20] [21] [22] Potential energy and number of hydrogen bonds between the RBD and ACE2. In (C), the averages and standard deviations are from five parallel runs (Figure 4) .

Three EELE molecules were initially put next to the three polybasic sites of the trimeric spike protein.

The system was equilibrated using the same process as that in the simulations in the absence of the tetrapeptide. One typical configuration is presented in Figure 3A . The inclusion of the tetrapeptide EELE can still preserve the spike protein-ACE2 complex (Figure 3A, B) . Nevertheless, the RBD-ACE2 intermolecular potential energy ( Figure 3C) remarkably dropped by 34% from -740 ± 70 kJ/mol without EELE to -490 ± 50 kJ/mol in the presence of EELE. Similarly, the number of RBD-ACE2 intermolecular hydrogen bonds dropped by 41%. Therefore, the presence of EELE greatly lessened RBD-ACE2 binding.

Of note is that only one subunit of the trimeric spike protein directly binds to the ACE2 receptor.

Consequently, the three polybasic cleavage sites have different distances to the ACE2 receptor and distinct local environment. Furthermore, the ACE2 receptor and the tetrapeptide EELE are both negatively charged (-28e for ACE2 and -3e for EELE). These effects collectively lead to the observation that the three tetrapeptides exhibited different binding behavior to the neighboring polybasic cleavage sites. Specifically, the polybasic cleavage site distributed the farthest from ACE2 stably binds to the tetrapeptide EELE for the whole simulation duration of 100 ns ( Figure 3A) ; in contrast, the two polybasic cleavage sites closer to ACE2 form weaker interactions with their neighboring tetrapeptides EELE, which became unbound at around 40 ns and 74 ns.

To experimentally design polybasic cleavage site-targeting clinical therapeutic peptides, a further increase in the oligopeptide hydrophobicity is required to elevate the stability in the SARS-CoV-2 spike protein-oligopeptide binding to determine if binding to all of the polybasic cleavage sites reduces the RBD-ACE2 overall binding energy even further. Meanwhile, the delivery of therapeutic peptides is known to be challenging concerning their short half-life due to the rapid proteolytic degradation and short circulation time due to the low molecular weight. 23, 24 These could be potentially overcome by covalently grafting oligopeptides at the side chains of peptide brush polymers, 25 or integrating them onto peptide amphiphiles 26 or PEGylation 27 .

Using large-scale all-atom explicit solvent simulations, we investigated the impact of the SARS-CoV-2 polybasic cleavage sites, which are distributed approximately 10 nm away from the RBD, on the binding affinity of the RBD and ACE2. It is found that in comparison to the wild type SARS-CoV-2 spike protein, a mutant with the deletion of N679SPRRA684 and a mutant with the substitution of R682R683 to E682E683 can both lessen the binding strength of the SARS-CoV-2 RBD and ACE2. The mutation-driven difference is ascribed to the electrostatic interactions between the spike proteins (wild type and mutants) and ACE2 and their hydration. In line with recent experimental findings, 2, 11 this work supports that distal mutations can impact the SARS-CoV-2 RBD-ACE2 binding affinity. Our design of a tetrapeptide, GluGluLeuGlu, that binds to the polybasic cleavage site of SARS-CoV-2, demonstrates that the polybasic cleavage site is a target for neutralizing SAR-CoV-2 RBD-ACE2 binding. This supports a recent finding that the non-RBD region of SARS-CoV-2 can be targetted by an antibody. 12 This work besides shedding light on the mechanism by which the SARS-CoV-2 spike protein binds to human cells, suggests therapeutic peptides design to target the polybasic cleavage sites that inhibit SARS-CoV-2 RBD binding to ACE2.

All-atom explicit solvent molecular dynamics (MD) simulations were performed using the package GROMACS (version 2016.4). 28 The CHARMM 36m potential 17 was employed for the proteins, Na + and Clions. The recommended CHARMM TIP3P water model 29 was employed with the structures constrained using the SETTLE algorithm 30 .

The SARS-CoV-2 spike protein-ACE2 binding structure was downloaded from the Zhang-Server. 16 The spike protein-ACE2 complex was reconstructed using the C-I-TASSER model 31 based on the protein identification number QHD43416 32 for the spike protein. Each subunit of the trimeric spike protein included the residues from M 1 to T1273 with the net charge of -7e, and the ACE2 has the residues from S19 to D615 with the net charge of -28e, with e being the elementary charge.

The spike protein-ACE2 complex was first solvated in a simulation box with an edge length of 16×18×24 nm 3 (Figure 4) . 0.15 M NaCl was added along with 49 Na + counterions of spike protein and ACE2. The system composition is listed in Table S1 in the Supporting Information. The energy of the simulation box was first minimized, which was followed by a simulation of 1 ps using the canonical ensemble (constant number of particles, volume, and temperature, NVT). The integration time step of 2 fs was employed with all the hydrogen-involved covalent bonds constrained using the LINCS algorithm 33, 34 .

Another simulation of 1 ps was subsequently conducted using the isothermal-isobaric ensemble (constant number of particles, pressure, and temperature, NPT). The velocity rescale temperature coupling was employed along with the Berendsen pressure coupling. In the following equilibration simulation of 10 ns, the Nosé-Hoover temperature coupling was applied along with the Parrinello-Rahman pressure coupling. 35 In all the equilibration simulations above, the coordinates of the non-hydrogen atoms of both the spike protein trimer and ACE2 were restrained using a force constant of 1000 kJ/mol/nm 2 to preserve the spike protein-ACE2 binding structure. The other parameters were the same as those in the production simulation below.

The spike protein-ACE2 complex (A) was solvated in a simulation box with 0.15 M NaCl (B). The spike protein trimer is colored cyan, silver, and blue, respectively, and ACE2 in orange. Na + and Clions are displayed using small blue and cyan beads, respectively, with water omitted for display. The polybasic cleavage sites (R682RAR685) are highlighted with bigger blue beads. The system was equilibrated (C). The WT spike protein was mutated by removing N 679SPRRA684 (mutant 1 with R685 in purple; D) and changing R682R683 to E682E683 (mutant 2 with E682EAR685 in red; E). Each simulation lasted 100 ns (C, D, E). Five parallel runs (10 ns each) were performed based on the configurations at 20, 40, 60, 80, and 100 ns. Same process was applied to the system with EELE tetrapeptides (F).

In the production simulation (Figure 4C) , the periodic boundary conditions were employed in all three dimensions. The neighbor searching was conducted up to 12 Å using the Verlet particle-based method and was updated every 20-time steps. The Lennard-Jones (LJ) 12-6 interactions were switched off from 10 to 12 Å via the potential-switch method in GROMACS. The short-range Coulomb interactions were truncated at the cut-off distance of 12 Å, and the long-range interactions were calculated using the Smooth Particle Mesh Ewald (PME) algorithm 36, 37 . The temperatures of proteins, ions, and water were separately coupled using the Nosé-Hover algorithm (reference temperature 298K, characteristic time 1 ps). The isotropic Parrinello-Rahman barostat was employed with the reference pressure of 1 bar, the characteristic time 4 ps, and the compressibility 4.5×10 -5 bar -1 . All the covalent bonds were constrained, which supported an integration time step of 2.5 fs. These parameters were recommended for the accurate reproduction of the original CHARMM simulation on lipid membrane system 38 The system had around 700,000 atoms and was computationally expensive. The performance was around 14 ns/day with 8 high-performance computing nodes, each with 24 CPU cores (Intel Haswell E5-2680, 2.5 GHz, 2 × 9.6 GT/s Intel® QPI, 2500 MHz).

The short-range Coulomb and LJ interaction energies ( Table S2 in the Supporting Information) were calculated using the GROMACS program gmx energy. The intermolecular hydrogen bonds were calculated using the GROMACS program gmx hbond. The structural criteria of hydrogen bond were applied that the donor (D) -acceptor (A) distance r DA ≤ 3.5 Å and the hydrogen−donor−acceptor angle θHDA ≤ 30°. 42, 43 

Based on the equilibrated structure, the wild type spike protein was mutated. For Mutant 1, the N679SPRRA684 residues were deleted from all the three subunits of the spike protein trimer. This was to mimic the experimentally reported mutant by Walls et al. 2 that the residues of T678NSPRRAR685 in the wild type spike protein of SARS-CoV-2 were mutated to T678--IL--R685. Accordingly, six Clions, which were distributed next to the six arginine residues of R 682R683 were removed to neutralize the system. The system was further equilibrated to relax the mutated region, which was followed by the production simulations. The simulation parameters were the same as those in the simulation on the wild type spike protein. Similarly, five parallel simulations were carried out based on the production simulation of 100 ns ( Figure 4D) .

For Mutant 2, the R682R683 residues were changed to E682E683 for all the three subunits of the spike protein trimer. Accordingly, the six Clions, which were distributed next to the six arginine residues (R682R683) were replaced with Na + ions to neutralize the system. Again, the simulation parameters were the same as those in the simulation on the wild type spike protein. The production simulation lasted 100 ns, where five parallel simulations were performed ( Figure 4E ).

Three tetrapeptides GluGluLeuGlu (EELE) were included, which were initially put next to the three polybasic cleavage sites (R682RAR685) of the trimeric wild type spike protein ( Figure 4F ). The spike protein-ACE2 complex and the tetrapeptide EELE were then solved in a simulation box with an edge length of 16×18×24 nm 3 . 0.15 M NaCl was added along with 9 Na + counterions of EELE and 49 Na + counterions of spike protein and ACE2 (Table S1 in the Supporting Information). The equilibration and productions were the same as whose for the wild type spike protein in the absence of the tetrapeptide.

The calculated RBD-ACE2 intermolecular Coulomb and Lennard-Jones interactions are presented in Table S2 in the Supporting Information.

The following files are available free of charge at http://pubs.acs.org/doi/XXX. 

The Proximal Origin of SARS-CoV-2

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Structural Basis for the Recognition of SARS-CoV-2 by Full-length Human ACE2

Structural Basis of Receptor Recognition by SARS-CoV-2

Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor

Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody

The First-in-class Peptide Binder to the SARS-CoV-2 Spike Protein

Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2

Spike Mutation Pipeline Reveals the Emergence of a more Transmissible Form of SARS-CoV-2

A Highly Conserved Cryptic Epitope in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV

The Spike Glycoprotein of the new Coronavirus 2019-nCoV Contains a Furin-like Cleavage Site Absent in CoV of the Same Clade

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1

CHARMM36m: An Improved Force Field for Folded and Intrinsically Disordered Proteins

Activating Peptides for Cellular Uptake via Polymerization into High Density Brushes

Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier

Water Follows Polar and Nonpolar Protein Surface Domains

Toward a Molecular Understanding of Protein Solubility: Increased Negative Surface Charge Correlates with Increased Solubility

Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions

Peptide Therapeutics: Current Status and Future Directions. Drug Discovery Today

Peptides Displayed as High Density Brush Polymers Resist Proteolysis and Retain Bioactivity

Peptide Supramolecular Materials for Therapeutics

Effect of PEGylation on Pharmaceuticals

GROMACS 4: Algorithms for Highly Efficient, Load Balanced, and Scalable Molecular Simulation

All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins

SETTLE: An Analytical Version of the SHAKE and RATTLE Algorithm for Rigid Water Models

Deep-learning contact-map guided protein structure prediction in CASP13

A new coronavirus associated with human respiratory disease in China

A Parallel Linear Constraint Solver for Molecular Simulation

LINCS: A Linear Constraint Solver for Molecular Simulations

Polymorphic Transitions in Single Crystals: A New Molecular Dynamics Method

Particle Mesh Ewald: An Nꞏlog(N) Method for Ewald Sums in Large Systems

A Smooth Particle Mesh Ewald Method

CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field

Mirror"-like Protein Dimers Stabilized by Local Heterogeneity at Protein Surfaces

Random Heteropolymers Preserve Protein Function in Foreign Environments

Single Chain Heteropolymers Transport Proton Selectively and Rapidly

Structure and Hydrogen Bond Dynamics of Water-Dimethyl Sulfoxide Mixtures by Computer Simulations

How Hydrogen Bonds Affect the Growth of Reverse Micelles around Coordinating Metal Ions